Short Bowel Syndrome Market

Market Overview:

The 7 major short bowel syndrome markets are expected to exhibit a CAGR of 20.52% during 2024-2034.

The short bowel syndrome market has been comprehensively analyzed in IMARC's new report titled "Short Bowel Syndrome Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Short bowel syndrome is a complex gastrointestinal disorder characterized by the inadequate functional length of the small intestine, often resulting from surgical resection or congenital conditions. It significantly impairs the body's ability to absorb nutrients and fluids, leading to a range of symptoms and nutritional deficiencies. Some of the common indications of this syndrome include severe diarrhea, malnutrition, dehydration, electrolyte imbalances, weight loss, and fatigue. Individuals suffering from the illness may also experience abdominal cramps, bloating, and an increased risk of developing complications like infections and kidney stones due to the malabsorption of key nutrients. The diagnosis of short bowel syndrome involves a combination of clinical evaluation, medical history review, physical exam, and various laboratory tests. Imaging techniques like X-rays, CT scans, and endoscopy can help to assess the length and function of the remaining intestine. The healthcare providers will further conduct blood workups to reveal nutritional deficiencies and electrolyte imbalances in patients.

The increasing cases of malabsorptive disorder resulting from the surgical removal of a significant segment of the small intestine, leading to an inadequate surface area for nutrient absorption, are primarily driving the short bowel syndrome market. In addition to this, the inflating utilization of essential medications, such as growth hormones, glutamine, anti-diarrheal agents, etc., to enhance intestinal absorption and manage associated symptoms is also creating a positive outlook for the market. Moreover, the widespread adoption of microbiome modulation techniques, since they involve manipulating the gut microbiota to improve nutrient uptake and intestinal health in individuals suffering from the disorder, is further bolstering the market growth. Apart from this, the rising demand for intestinal rehabilitation programs that focus on dietary adjustments, medication optimization, and parenteral nutrition tapering to boost the quality of life and enhance treatment outcomes is acting as another significant growth-inducing factor. Additionally, the emerging popularity of surgical interventions, such as intestinal transplantation, to treat patients who are non-responsive to other therapies is also augmenting the market growth. Furthermore, advances in regenerative medicine, which aims to regenerate or replace damaged intestinal tissue using stem cells and tissue engineering, are expected to drive the short bowel syndrome market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the short bowel syndrome market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for short bowel syndrome and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the short bowel syndrome market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the short bowel syndrome market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the short bowel syndrome market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current short bowel syndrome marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance    
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the short bowel syndrome market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the short bowel syndrome market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the short bowel syndrome market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of short bowel syndrome across the seven major markets?
• What is the number of prevalent cases (2018-2034) of short bowel syndrome by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of short bowel syndrome by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with short bowel syndrome across the seven major markets?
• What is the size of the short bowel syndrome patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of short bowel syndrome?
• What will be the growth rate of patients across the seven major markets?
   

Short Bowel Syndrome: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for short bowel syndrome drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the short bowel syndrome market?
• What are the key regulatory events related to the short bowel syndrome market?
• What is the structure of clinical trial landscape by status related to the short bowel syndrome market?
• What is the structure of clinical trial landscape by phase related to the short bowel syndrome market?
• What is the structure of clinical trial landscape by route of administration related to the short bowel syndrome market?